Alison Kanski

Articles Authored by Alison Kanski
SABCS Studies Explore Germline Mutations' Varied Effects on Breast Cancer Risk, Survival Outcomes
Premium
Researchers examine the interplay of germline cancer risk mutations and somatic mutations, and how surgery type and contraceptives impact breast cancer risk.

Tukysa-Kadcyla Combo Shows Efficacy in HER2-Positive Breast Cancer Patients With Brain Metastases
Premium
Researchers at SABCS said data from HER2CLIMB-02 could influence imaging and treatment strategies for patients whose breast cancer has spread to the brain.

Role of SPOP Mutations in Prostate, Endometrial Cancer Come Into Focus in Retrospective Analysis
Premium
Using Caris Life Sciences' database, researchers found that prostate and endometrial cancers with SPOP mutations have distinct immune characteristics.

Mass General Tries to Show Value of Virtual Precision Medicine Clinic to Community Oncologists
Premium
The virtual clinic helped community oncologists interpret genomic testing results and led a third of cases to be enrolled in precision medicine drug trials.

Study Secures EGFR Mutation's Role in Inherited Lung Cancer Risk; Raises Questions About Guidelines
Premium
In a prospective study, patients with an EGFR T790M somatic mutation at diagnosis had a 50 percent chance of having a germline mutation, suggesting the need for more specific guidelines.

AccessHope Real-World Data Study Identifies Molecular Testing Gaps in Pancreatic Cancer Care
Premium
Out of around 100 cases reviewed by subspecialists, most completed recommended, guideline-concordant germline and somatic testing, but many still did not.

Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.

Executives noted that its two recent acquisitions, Mirati Therapeutics and Turning Point Therapeutics, underscore its shift away from immunotherapy.

Amgen Eager for Regulatory Discussions After Lumakras-Vectibix CodeBreaK 300 Data in Colon Cancer
Premium
At ESMO, experts found the combination promising in KRAS G12C-mutated colorectal cancer patients, though some want more safety and overall survival data.

Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.